Frequently Asked Questions (FAQ)

This site started as a personal account of using low-dose buprenorphine for emotional regulation and interpersonal stability. It has since grown to include research synthesis, explanatory writing, and prescriber-facing resources. It is written for:

• People with BPD, CPTSD, or severe affective dysregulation who are curious whether opioid-system-targeting treatments might explain their lived experience
• Clinicians and researchers looking for accessible summaries of the literature alongside a detailed first-person account
• Skeptical readers who want to understand what I am actually claiming — and what I am not

It is not a protocol or recommendation.

Yes. cptsd.fyi covers the same biology and the same treatment approach, framed around complex trauma rather than BPD. The diagnosis is different; the underlying argument is the same.

If someone won't engage with the BPD label but recognizes themselves in descriptions of emotional instability and relational sensitivity, that site may be an easier entry point.

A few things to know going in: cptsd.fyi doesn't yet have its own prescriber resources, so the resources page there links to this site. The research page on cptsd.fyi is also drawn from the same literature, which remains primarily BPD-focused — I'm actively working through the CPTSD-specific literature and will add as I'm able. Explanatory writing and blog posts currently live here as well, not on cptsd.fyi.

No.

I am not telling anyone what to take, how much to take, or how to obtain medication. I describe what I did under medical supervision, what changed for me, and what the research literature says about why it may have worked.

Sharing personal experience is my right. Acting on it without a clinician is your responsibility. I do not condone or encourage acting on it without a clinician.

Because it worked when nothing else did.

Before medication, my baseline state was emotional emptiness punctuated by chaos. Intensity (good or bad) temporarily made me feel regulated. Relationships were unstable because my nervous system was unstable.

Low-dose buprenorphine didn’t blunt my emotions. It made them manageable. The chaos stopped being necessary.

No. I’m saying that opioid-system dysfunction plausibly explains some core features of BPD for some people, including:

• Chronic internal distress and emptiness
• Extreme interpersonal sensitivity
• Reliance on external connection to self-regulate

That framing is already present in the psychiatric literature. My experience aligns with it strongly.

Only if you assume there is one settled, complete theory of BPD — which there isn’t.

Most people encounter BPD through treatment models like DBT. DBT is a skills-based therapy designed to reduce harm and improve functioning. It was not built to explain the full neurobiology of the disorder, and it doesn’t need to be.

A neurobiological framing doesn’t replace psychological or developmental models. It adds another layer. Different models answer different questions: how symptoms develop, how they’re maintained, and how they can be reduced.

If a particular model says a medication “shouldn’t” help, but real people reliably report that it does, that’s a signal to update the model — not dismiss the experience.

The goal here isn’t theoretical purity. It’s understanding why certain symptoms respond to certain interventions, and being honest about what actually reduces suffering.

It might — depending on what someone’s core struggles actually are.

CPTSD and BPD can overlap in areas like emotional reactivity, interpersonal sensitivity, and difficulty staying regulated. That overlap is one reason the two diagnoses are often confused or argued about.

Some people diagnosed with CPTSD mainly struggle with trauma memories, flashbacks, or hypervigilance tied to specific past events. Others experience a more constant baseline instability, where emotions and relationships are hard to regulate even when nothing obviously traumatic is happening.

My experience suggests that when the core problem is baseline emotional instability and heavy reliance on connection to feel okay, targeting the opioid system can change how that regulation works. That pattern may show up in some people labeled CPTSD, but it will not apply to everyone.

This isn’t a claim that buprenorphine “treats CPTSD.” It’s an observation that diagnostic labels don’t always line up cleanly with what’s actually happening in someone’s nervous system.

DBT teaches skills. Skills require a nervous system that can use them.

For me, DBT helped around the edges. Medication changed my baseline.

For some people, DBT is enough. For others, insisting on DBT alone becomes a form of gatekeeping treatment access.

Yes.

Buprenorphine is a real opioid with real risks. I am not minimizing that. At the same time, it is pharmacologically unusual: partial agonism, ceiling effects, and long receptor binding make it very different from short-acting opioids.

No — and the idea that “it’s all just opioids” is where this line of thinking goes wrong. Buprenorphine is not “heroin but weaker.” It behaves differently at the receptor level and in practice.

Buprenorphine has very high receptor affinity and binds for a long time. That means it can act as a stabilizing occupier of opioid receptors: providing some opioid signaling while also reducing the impact of other opioid inputs that would otherwise bind strongly and fluctuate rapidly.

For people whose emotional regulation is tightly coupled to the opioid system, that can matter a lot. It can blunt the relief or “high” from chaos, self-harm, or other high-intensity regulation strategies, while still preventing the system from dropping into a severely dysregulated low state.

Short-acting full agonist opioids (including heroin and medications like oxycodone) tend to produce sharper peaks followed by stronger rebounds. That volatile pattern is the opposite of what helped me. My experience of buprenorphine was baseline stability, not bigger highs.

The important distinction here is not “opioid versus non-opioid,” or “street drug versus prescription.” It’s receptor affinity, partial versus full agonism, duration of action, and how stable the signaling is over time. Those differences are why “just take heroin” is not only flippant, but conceptually wrong.

I take this seriously.

I was opioid-naïve, monitored by a physician, and stable at a very low dose on a set schedule. I do not escalate doses. I do not use it to chase euphoria.

Risk is not zero. It is managed, not ignored.

Reactions to opioids in people with MCAS can be highly individual. Some opioids are more likely than others to trigger mast cell activation, but “lower risk” does not mean “no risk.”

Buprenorphine is often described as having a lower tendency to trigger mast cell reactions compared to some other opioids, but that does not guarantee tolerance for any specific person. Past reactions to opioids are important information and should be taken seriously.

This is an area where caution matters. Any consideration of buprenorphine in the context of MCAS should involve a clinician who understands both conditions, close monitoring, and a willingness to stop if adverse reactions occur.

This site cannot assess individual safety. The key point is that variability is real, and continued use in the face of clear reactions is not benign.

Because people ask.

I try to mention doses only to contextualize scale, not to provide a starting point. Any mention of milligrams should be read as descriptive, not prescriptive.

If dosage details feel activating or unsafe for where you are right now, it's okay to step away. This content will still be here when you're ready.

For me, effects were noticeable within about an hour when taken sublingually, with full stabilization over a few days.

Different people report different onset times depending on formulation, administration method, and individual biology.

Long enough for absorption. I’m deliberately vague here because technique optimization crosses into instruction.

Your prescriber should guide this.

Indirectly, yes.

My sleep improved because I was no longer carrying constant emotional volatility into bedtime. The medication didn’t sedate me; it removed the internal chaos that kept me awake.

It made me more myself.

I still feel deeply. I still care intensely. I just don’t spiral or destabilize when connection fluctuates.

If someone prefers me dysregulated, they may experience this as a “personality change.” That says more about what they needed from my instability than about who I actually am.

Because people ask about alternatives.

LDN interacts with the opioid system differently and may be sufficient for some people, especially those without the same baseline instability.

I used ultra-low-dose naltrexone during tapering and found it helpful.

Buprenorphine sits at an unusual crossroads in medicine. It is primarily associated with addiction treatment, is tightly regulated, and carries significant stigma — even though it is legally allowed to be prescribed off-label.

Many clinicians are trained to think of buprenorphine only in the context of opioid use disorder — and increasingly, chronic pain — but not as a medication that might affect emotional regulation or interpersonal stability. Prescribing it outside those contexts can feel professionally risky, unfamiliar, or unsupported, even when it is technically permitted.

Mental health care is also still organized around diagnostic categories rather than underlying mechanisms. When a patient says a medication helps in a way that doesn’t fit a standard treatment pathway, that experience is often discounted rather than investigated.

None of this means the difficulty is a judgment about a particular patient. It reflects how regulation, training, stigma, and medical culture shape what clinicians feel able to prescribe.

For practical next steps, see How do I get treatment?

Talk to your primary care provider. Buprenorphine is prescribed off-label for this use, which means most clinicians won't raise it unprompted — you'll likely need to bring it up yourself.

The prescriber guide on the resources page is written to support that conversation. It covers the rationale, the relevant literature, and what a reasonable protocol looks like.

If your current provider isn't a good fit, addiction medicine physicians and psychiatric nurse practitioners tend to be more familiar with buprenorphine and more open to off-label use. Addiction clinics are worth considering, particularly if substance use is part of your picture — clinicians there prescribe buprenorphine routinely. That said, addiction clinic capacity is limited, and those resources are prioritized for people at elevated risk of death without access to treatment. It's worth pursuing other avenues first if that doesn't describe your situation.

For more on why this is difficult in the first place, see Why is it so hard to get buprenorphine prescribed for this kind of use?

Kratom acts on opioid receptors and some people with BPD have reported that it helps with emotional regulation in ways that parallel what I describe with buprenorphine. The pharmacology is relevant. The reports from people who use it are relevant. Together, that's worth taking seriously — not dismissing.

Kratom is more accessible than buprenorphine because it does not require a prescription. For people who cannot access sympathetic prescribers or who face the barriers described elsewhere on this page, that accessibility matters.

At the same time, kratom is unregulated, variable in potency and composition, and carries real considerations for sustained use -- including physical dependence, which can develop with regular use as it can with many medications. That's not inherently a reason to avoid it, but it matters more when supply and legal status are unpredictable. I do not have lived experience with kratom and cannot speak to dosing, sourcing, or what sustained use looks like. I would not be comfortable writing a guide for something I haven't done myself.

This does not extend to synthetic kratom derivatives like 7-hydroxymitragynine (7-OH). Unlike natural leaf kratom, which has shown a relatively favorable safety profile in animal and human studies, 7-OH carries risks more characteristic of conventional opioids: severe dependence, withdrawal, and respiratory depression significant enough to cause overdose. I don't recommend it and won't be covering it here.

Because this topic attracts moral panic, bad-faith readings, and over-interpretation. Precision is self-defense.

No.

I am anti-dogma.

I believe psychiatry works best when it listens to patients, updates its models, and tolerates complexity.

Because silence benefits stigma.

If even one person recognizes themselves in this and asks better questions of their clinician, it’s worth it.

• Some suffering labeled “personality” may be neurobiological
• Stability is not the same as numbness
• People deserve treatments that work for their nervous system

Talk to a clinician. Read the literature. Be honest about risks. Do not self-experiment recklessly.

And remember: my experience is evidence of possibility, not proof of universality.